Lupin's Goa facility may face regulatory action, says USFDA

The USFDA has stated that it may withhold approval of any pending
applications or supplements in which this facility is listed," it
added.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupins-goa-facility-may-face-regulatory-action-says-usfda/articleshow/69586425.cms

Comments

Popular posts from this blog

Clinical Database Management Professional Vacancy @ Teva

Pharma Production Executive Post Vacancy @ Intas

Biotecnika Times – Newsletter 28.02.2020 – DST Women Scientist WOS B, DBT-IOC Recruitment